Tema Etfs LLC Buys Shares of 58,935 Genmab A/S (NASDAQ:GMAB)

Tema Etfs LLC acquired a new stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 58,935 shares of the company's stock, valued at approximately $1,230,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. EverSource Wealth Advisors LLC lifted its stake in Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after acquiring an additional 939 shares during the period. Lindbrook Capital LLC increased its holdings in shares of Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after purchasing an additional 950 shares in the last quarter. Barclays PLC increased its holdings in shares of Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after purchasing an additional 2,285 shares in the last quarter. Cromwell Holdings LLC increased its holdings in shares of Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock valued at $60,000 after purchasing an additional 2,496 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Genmab A/S during the 4th quarter valued at approximately $60,000. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Stock Up 0.7%

Shares of Genmab A/S stock traded up $0.15 during trading hours on Tuesday, reaching $20.33. 1,029,673 shares of the company's stock were exchanged, compared to its average volume of 1,114,959. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $30.06. The company has a market capitalization of $13.04 billion, a P/E ratio of 11.68, a price-to-earnings-growth ratio of 2.65 and a beta of 1.04. The business has a fifty day moving average of $19.75 and a two-hundred day moving average of $20.72.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.08. The firm had revenue of $715.00 million for the quarter, compared to analysts' expectations of $5.17 billion. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. As a group, research analysts predict that Genmab A/S will post 1.45 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. BNP Paribas raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 11th. William Blair raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price for the company in a report on Thursday, February 13th. Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. Finally, Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $39.17.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.